LH · 10-Q · 2026Q3

LABCORP HOLDINGS INC.

Filed 2026-10-30 · Healthcare · View original filing on EDGAR

Everything LH's SEC filings said, ranked

Ranked Events

• Acquisition / Partnership / DivestitureImportance 65 · Surprise 60
  On June 28, 2026, Labcorp agreed to acquire select assets of an outreach laboratory services business for approximately $155.0 million, subject to customary closing conditions and approvals. On October 15, it announced…
• Liquidity and Debt PositionImportance 56 · Surprise 58
  At September 30, 2026, Labcorp held $261.8 million of cash and had $1,000.0 million available under its revolving credit facility, which expires in 2030. Nine-month operating cash flow increased $174.5 million year…
• Restructuring and HeadcountImportance 53 · Surprise 82
  Net restructuring and other charges increased to $15.9 million in the third quarter of 2026 from $5.9 million in the prior-year quarter. The 2026 quarter included $12.3 million of severance and other personnel costs,…
• Capital Return ProgramImportance 52 · Surprise 42
  On July 8, 2026, the board authorized an additional $1,000.0 million of common-stock repurchases, bringing remaining authorization to $1,378.6 million at September 30, with no expiration date. Common-stock repurchases…
• Capital ExpendituresImportance 51 · Surprise 38
  Capital expenditures were $404.2 million for the nine months ended September 30, 2026, up from $310.6 million in the comparable 2025 period. The 2026 expenditure was 3.6% of revenue and supported core-business growth,…
• Equity Method LossesImportance 45 · Surprise 64
  Equity method loss, net, increased 109.3% to $11.0 million in the third quarter of 2026 from $5.2 million in the prior-year quarter. For the first nine months, the loss increased 207.3% to $22.3 million from $7.2…
• Operating Income and MarginsImportance 45 · Surprise 40
  Third-quarter operating income increased 1.4% to $402.1 million, while segment operating income rose 11.7% to $650.6 million. Dx operating income increased 9.2% to $491.6 million and its margin expanded 40 basis points…
• End-Market Demand TrendsImportance 43 · Surprise 32
  For the three months ended September 30, 2026, Labcorp’s revenue increased 6.9% year over year, driven by 5.5% organic growth. Diagnostics (Dx) revenue grew 6.5%, with requisition volume up 4.8% and price/mix up 1.7%;…
• Revenue Performance and MixImportance 43 · Surprise 32
  For the three months ended September 30, 2026, revenue was $3,810.0 million, up 6.9% year over year; nine-month revenue was $11,078.7 million, up 6.2%. Third-quarter growth included 5.5% organic revenue growth and a…
• FX / Currency ImpactImportance 38 · Surprise 46
  For the nine months ended September 30, 2026, Labcorp recognized $13.1 million of foreign currency transaction losses, compared with $8.0 million in the corresponding 2025 period, an increase of approximately 64%.…
• Interest Rate and Refinancing ExposureImportance 38 · Surprise 24
  The Company’s 2026 Term Loan, accounts receivable facility, and revolving credit facility bear variable interest rates. Labcorp states that higher benchmark rates would further increase interest expense on…
• Income Tax Rate ChangesImportance 30 · Surprise 40
  The effective tax rate fell to 19.8% in the third quarter of 2026 from 22.4% in the third quarter of 2025, while income tax provision declined to $64.9 million from $75.5 million. The company attributed the quarterly…
• Operating Expense TrendsImportance 29 · Surprise 22
  Third-quarter SG&A increased 10.5% to $611.4 million, and rose to 16.0% of revenue from 15.5%, primarily due to higher personnel costs and LaunchPad costs, partly offset by revenue growth. Nine-month SG&A increased…
• Gross Margin DriversImportance 25 · Surprise 32
  For the third quarter of 2026, cost of revenues increased 6.4% to $2,701.9 million, while cost of revenues declined to 70.9% of revenue from 71.2%. For the first nine months, cost of revenues increased 5.8% to $7,844.8…

Revenue by Product (in millions)